NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Company Overview - NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4] - The company is developing NRX-101, which has received FDA designation as an investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain [4] - NRx Pharmaceuticals has initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on clinical trial results and data from French health authorities [5] HOPE Therapeutics - HOPE Therapeutics, Inc. is a wholly-owned subsidiary of NRx Pharmaceuticals, aiming to create a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for suicidal depression [6] - The company plans to integrate a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [6] Upcoming Events - NRx Pharmaceuticals will present a company update at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 9:20 to 9:50 AM EST [2] - Management will also be available for one-on-one meetings in New York from February 10th to 12th, 2025, during the BIO CEO & Investor Conference [3]